{
    "paper_id": "5de6b4de529c8d5c4b015286f3f2ff85f521733f",
    "metadata": {
        "title": "Journal Pre-proof Current development of COVID-19 diagnostics, vaccines and therapeutics Current development of COVID-19 diagnostics, vaccines and therapeutics 1 2",
        "authors": [
            {
                "first": "Naru",
                "middle": [],
                "last": "Zhang",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Zhejiang University City 6 College",
                    "location": {
                        "settlement": "Hangzhou",
                        "country": "China"
                    }
                },
                "email": ""
            },
            {
                "first": "Chaoqun",
                "middle": [],
                "last": "Li",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Zhejiang University City 6 College",
                    "location": {
                        "settlement": "Hangzhou",
                        "country": "China"
                    }
                },
                "email": ""
            },
            {
                "first": "Yue",
                "middle": [],
                "last": "Hu",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Zhejiang University City 6 College",
                    "location": {
                        "settlement": "Hangzhou",
                        "country": "China"
                    }
                },
                "email": ""
            },
            {
                "first": "Kangchen",
                "middle": [],
                "last": "Li",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Jintian",
                "middle": [],
                "last": "Liang",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Zhejiang University City 6 College",
                    "location": {
                        "settlement": "Hangzhou",
                        "country": "China"
                    }
                },
                "email": ""
            },
            {
                "first": "Lili",
                "middle": [],
                "last": "Wang",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Zhejiang University City 6 College",
                    "location": {
                        "settlement": "Hangzhou",
                        "country": "China"
                    }
                },
                "email": ""
            },
            {
                "first": "Lanying",
                "middle": [],
                "last": "Du",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "New York Blood Center",
                    "location": {
                        "region": "New York",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "Shibo",
                "middle": [],
                "last": "Jiang",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "New York Blood Center",
                    "location": {
                        "region": "New York",
                        "country": "USA"
                    }
                },
                "email": "shibojiang@fudan.edu.cnsj"
            },
            {
                "first": "N",
                "middle": [],
                "last": "Zhang",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "C",
                "middle": [],
                "last": "Li",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Y",
                "middle": [],
                "last": "Hu",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "K",
                "middle": [],
                "last": "Li",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "J",
                "middle": [],
                "last": "Liang",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "L",
                "middle": [],
                "last": "Wang",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "L",
                "middle": [],
                "last": "Du",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "S",
                "middle": [],
                "last": "Jiang",
                "suffix": "",
                "affiliation": {},
                "email": ""
            }
        ]
    },
    "abstract": [
        {
            "text": "A novel coronavirus, designated as SARS-CoV-2, first emerged in Wuhan City, Hubei 17 Province, China, in late December 2019. The rapidly increasing number of cases has 18 caused worldwide panic. In this review, we describe some currently applied 19 diagnostic approaches, as well as therapeutics and vaccines, to prevent, treat and 20 control further outbreaks of SARS-CoV-2 infection. 21 22",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": "In late December 2019, a pneumonia of unknown etiology emerged in Wuhan City, 27 Hubei Province, China. Patients presenting with acute respiratory failure were seen in 28 the ER and then admitted to ICU facilities for further treatment [1] . The causative . Although the mortality rate of SARS-CoV-2 is lower than that of 50 MERS-CoV and SARS-CoV, its transmissibility (median R 0 : 5.7) is much higher than 51 that of either MERS-CoV (R 0 : <1) or SARS-CoV (R 0 : 3) [ Up to now, SARS-CoV-2 has been detected from clinical specimens analyzed by under development by several organizations through international collaborations [32] .",
            "cite_spans": [
                {
                    "start": 78,
                    "end": 80,
                    "text": "27",
                    "ref_id": null
                },
                {
                    "start": 236,
                    "end": 239,
                    "text": "[1]",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 322,
                    "end": 324,
                    "text": "50",
                    "ref_id": "BIBREF46"
                },
                {
                    "start": 468,
                    "end": 469,
                    "text": "[",
                    "ref_id": null
                },
                {
                    "start": 626,
                    "end": 630,
                    "text": "[32]",
                    "ref_id": "BIBREF22"
                }
            ],
            "ref_spans": [],
            "section": "26"
        },
        {
            "text": "The pulmonary surfactant-biomimetic nanoparticles used to potentiate heterosubtypic 152 influenza immunity can be used as adjuvant to enhance the immunogenicity of 153 SARS-CoV-2 subunit vaccines [33] . roxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or).",
            "cite_spans": [
                {
                    "start": 196,
                    "end": 200,
                    "text": "[33]",
                    "ref_id": "BIBREF23"
                }
            ],
            "ref_spans": [],
            "section": "151"
        },
        {
            "text": "Another interesting strategy is to use convalescent plasma (CP) as treatment, but it 238 should be noted that CP should be collected within two weeks after recovery to ensure 239 a high neutralization antibody titer [50] . It was reported that SARS-CoV-2 isolated ",
            "cite_spans": [
                {
                    "start": 85,
                    "end": 88,
                    "text": "238",
                    "ref_id": null
                },
                {
                    "start": 216,
                    "end": 220,
                    "text": "[50]",
                    "ref_id": "BIBREF46"
                }
            ],
            "ref_spans": [],
            "section": "237"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Clinical features of 314 patients infected with 2019 novel coronavirus in Wuhan, China",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Huang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Ren",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "315",
            "issn": "",
            "pages": "497--506",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "A distinct name is 317 needed for the new coronavirus",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Shi",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Shu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Song",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "F"
                    ],
                    "last": "Gao",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Tan",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "395",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Early transmission 319 dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl 320",
            "authors": [
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Guan",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Tong",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Med",
            "volume": "382",
            "issn": "",
            "pages": "1199--207",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Potential interventions for novel coronavirus in China: A 322 systematic review",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Med Virol",
            "volume": "92",
            "issn": "",
            "pages": "479--90",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Epidemiology, genetic 324 recombination, and pathogenesis of coronaviruses",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Su",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Wong",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Shi",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Ack",
                    "middle": [],
                    "last": "Lai",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Trends Microbiol",
            "volume": "24",
            "issn": "",
            "pages": "325--490",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Middle East respiratory syndrome coronavirus fusion inhibitor",
            "authors": [],
            "year": 2019,
            "venue": "Nat Commun",
            "volume": "328",
            "issn": "",
            "pages": "1539--1584",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Subunit vaccines against emerging 374 pathogenic human coronaviruses",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Shang",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Du",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Front Microbiol",
            "volume": "11",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "An emerging coronavirus causing pneumonia outbreak 376 in Wuhan, China: calling for developing therapeutic and prophylactic 377 strategies",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Du",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Shi",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Emerg Microbes Infect",
            "volume": "9",
            "issn": "",
            "pages": "275--282",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "Inovio Collaborating With Beijing Advaccine To Advance 379 INO-4800 Vaccine Against New Coronavirus In China",
            "authors": [],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Partner-with-CEPI-in-Phase-12-Clinical-Trial-of-INOVIOs-COVID-19",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "DNA-Vaccine-in-South-Korea/default.aspx. Accessed 22",
            "authors": [],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "Kaiser 384",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "Permanente launches first coronavirus vaccine trial",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "MERS-CoV spike protein: a key 388 target for antivirals",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Du",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Lu",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Expert Opin Ther Targets",
            "volume": "21",
            "issn": "",
            "pages": "131--174",
            "other_ids": {}
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "MERS-CoV spike protein: Targets 390 for vaccines and therapeutics",
            "authors": [
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Wong",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Lu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Yan",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "F"
                    ],
                    "last": "Gao",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Antiviral Res",
            "volume": "133",
            "issn": "",
            "pages": "165--77",
            "other_ids": {}
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "Introduction of neutralizing 392 immunogenicity index to the rational design of MERS coronavirus subunit 393 vaccines",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Du",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Tai",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Zhu",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Sun",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Nat Commun",
            "volume": "7",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "The spike protein of 395",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Du",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "He",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "J"
                    ],
                    "last": "Zheng",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF19": {
            "ref_id": "b19",
            "title": "Clover initiates development of recombinant 398 subunit-trimer vaccine for Wuhan coronavirus (2019-nCoV)",
            "authors": [],
            "year": 2020,
            "venue": "Clover Biopharmaceuticals",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "Characterization of the 400 receptor-binding domain (RBD) of 2019 novel coronavirus: implication for 401 development of RBD protein as a viral attachment inhibitor and vaccine",
            "authors": [
                {
                    "first": "W",
                    "middle": [],
                    "last": "Tai",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "He",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Pu",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Voronin",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Cell",
            "volume": "402",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF22": {
            "ref_id": "b22",
            "title": "The SARS-CoV-2 vaccine 404 pipeline: an overview",
            "authors": [
                {
                    "first": "W",
                    "middle": [
                        "H"
                    ],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "U",
                    "middle": [],
                    "last": "Strych",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "J"
                    ],
                    "last": "Hotez",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "E"
                    ],
                    "last": "Bottazzi",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Curr Trop Med Rep",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF23": {
            "ref_id": "b23",
            "title": "Pulmonary 406 surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza 407 immunity",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Fu",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Lu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Science",
            "volume": "367",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF24": {
            "ref_id": "b24",
            "title": "China coronavirus: Hong Kong researchers have already developed 409 vaccine but need time to test it, expert reveals",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Cheung",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF25": {
            "ref_id": "b25",
            "title": "Codagenix raises $20 million for a new flu vaccine and other 413 therapies",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Shieber",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF27": {
            "ref_id": "b27",
            "title": "The COVID-19 vaccine development landscape. Nat Rev Drug 418 Discov 2020",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF28": {
            "ref_id": "b28",
            "title": "Accessed 28",
            "authors": [],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF29": {
            "ref_id": "b29",
            "title": "Partner with CEPI in Phase 1/2 Clinical Trial of 423 INOVIO's COVID-19 DNA Vaccine in South Korea",
            "authors": [
                {
                    "first": "Inovio",
                    "middle": [],
                    "last": "Ivi",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF30": {
            "ref_id": "b30",
            "title": "Partner-with-CEPI-in-Phase-12-Clinical-Trial-of-INOVIOs 426 -COVID-19-DNA-Vaccine-in-South-Korea/default.aspx",
            "authors": [
                {
                    "first": "-Knih-To",
                    "middle": [],
                    "last": "Vio-",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF31": {
            "ref_id": "b31",
            "title": "SARS-CoV-2 vaccines: status report",
            "authors": [
                {
                    "first": "F",
                    "middle": [],
                    "last": "Amanat",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Krammer",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Immunity",
            "volume": "429",
            "issn": "",
            "pages": "583--592",
            "other_ids": {}
        },
        "BIBREF32": {
            "ref_id": "b32",
            "title": "A trial of 431 lopinavir-ritonavir in adults hospitalized with severe COVID-19",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Cao",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Wen",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Fan",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "N Engl J",
            "volume": "432",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF33": {
            "ref_id": "b33",
            "title": "Case of the index 434 patient who caused tertiary transmission of COVID-19 infection in Korea: the 435 application of lopinavir/ritonavir for the treatment of COVID-19 infected 436 pneumonia monitored by quantitative RT-PCR",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Lim",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Jeon",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "Y"
                    ],
                    "last": "Shin",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "J"
                    ],
                    "last": "Kim",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "M"
                    ],
                    "last": "Seong",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "J"
                    ],
                    "last": "Lee",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Korean Med Sci",
            "volume": "35",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF34": {
            "ref_id": "b34",
            "title": "Discovering drugs to treat coronavirus disease 2019 439 (COVID-19)",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Dong",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Gao",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Drug Discov Ther",
            "volume": "14",
            "issn": "",
            "pages": "58--60",
            "other_ids": {}
        },
        "BIBREF36": {
            "ref_id": "b36",
            "title": "A randomized, controlled trial of Ebola virus disease therapeutics",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF38": {
            "ref_id": "b38",
            "title": "Remdesivir and 444 chloroquine effectively inhibit the recently emerged novel coronavirus 445 (2019-nCoV) in vitro",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Cao",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Cell Res",
            "volume": "30",
            "issn": "",
            "pages": "269--71",
            "other_ids": {}
        },
        "BIBREF40": {
            "ref_id": "b40",
            "title": "First case of 2019 novel coronavirus in the United States",
            "authors": [],
            "year": 2020,
            "venue": "N Engl J Med",
            "volume": "448",
            "issn": "",
            "pages": "929--965",
            "other_ids": {}
        },
        "BIBREF41": {
            "ref_id": "b41",
            "title": "Effects of 450 chloroquine on viral infections: an old drug against today's diseases?",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Savarino",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "R"
                    ],
                    "last": "Boelaert",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Cassone",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Majori",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Cauda",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Lancet 451 Infect Dis",
            "volume": "3",
            "issn": "",
            "pages": "722--729",
            "other_ids": {}
        },
        "BIBREF42": {
            "ref_id": "b42",
            "title": "Breakthrough: Chloroquine phosphate has shown 453 apparent efficacy in treatment of COVID-19 associated pneumonia in clinical 454 studies",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Gao",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Tian",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Biosci Trends",
            "volume": "14",
            "issn": "",
            "pages": "72--75",
            "other_ids": {}
        },
        "BIBREF43": {
            "ref_id": "b43",
            "title": "Hydroxychloroquine, a 456 less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 457 infection in vitro",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Cao",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Cell Discov",
            "volume": "6",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF45": {
            "ref_id": "b45",
            "title": "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of 460 23 an open-label non-randomized clinical trial",
            "authors": [],
            "year": 2020,
            "venue": "Int J Antimicrob Agents",
            "volume": "461",
            "issn": "105949",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF46": {
            "ref_id": "b46",
            "title": "The epidemiology, diagnosis 463 and treatment of COVID-19",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Zhai",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Ding",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Long",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Zhong",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Int J Antimicrob Agents",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF47": {
            "ref_id": "b47",
            "title": "A pneumonia 465 outbreak associated with a new coronavirus of probable bat origin",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [
                        "L"
                    ],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [
                        "G"
                    ],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Nature",
            "volume": "466",
            "issn": "2020",
            "pages": "270--273",
            "other_ids": {}
        },
        "BIBREF48": {
            "ref_id": "b48",
            "title": "Treatment of 5 critically 468 ill patients with COVID-19 with convalescent plasma",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Shen",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Yuan",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "JAMA",
            "volume": "323",
            "issn": "",
            "pages": "469--1582",
            "other_ids": {}
        },
        "BIBREF49": {
            "ref_id": "b49",
            "title": "Effectiveness of convalescent 471 plasma therapy in severe COVID-19 patients",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Duan",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Qu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Proc Natl Acad Sci",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF51": {
            "ref_id": "b51",
            "title": "Human polyclonal immunoglobulin G from transchromosomic bovines 474 inhibits MERS-CoV in vivo",
            "authors": [],
            "year": 2016,
            "venue": "Sci Transl Med",
            "volume": "8",
            "issn": "",
            "pages": "326--347",
            "other_ids": {}
        },
        "BIBREF52": {
            "ref_id": "b52",
            "title": "Potent binding of 2019 novel 476 coronavirus spike protein by a SARS coronavirus-specific human monoclonal 477 antibody",
            "authors": [
                {
                    "first": "X",
                    "middle": [],
                    "last": "Tian",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Huang",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Xia",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Lu",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Shi",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Emerg Microbes Infect",
            "volume": "9",
            "issn": "",
            "pages": "382--387",
            "other_ids": {}
        },
        "BIBREF53": {
            "ref_id": "b53",
            "title": "Interaction between 479 heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: 480 implications for virus fusogenic mechanism and identification of fusion 481 inhibitors",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Xiao",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "He",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Niu",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "R"
                    ],
                    "last": "Escalante",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Lancet",
            "volume": "363",
            "issn": "",
            "pages": "938--985",
            "other_ids": {}
        },
        "BIBREF54": {
            "ref_id": "b54",
            "title": "Inhibition of SARS-CoV-2 483 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion 484 inhibitor targeting its spike protein that harbors a high capacity to mediate 485 membrane fusion",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Xia",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Lan",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Feng",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Cell Res",
            "volume": "30",
            "issn": "",
            "pages": "343--55",
            "other_ids": {}
        },
        "BIBREF55": {
            "ref_id": "b55",
            "title": "Fusion mechanism of 487 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Xia",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Zhu",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Lan",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Cell",
            "volume": "488",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF57": {
            "ref_id": "b57",
            "title": "A 490 pan-coronavirus fusion inhibitor targeting the HR1 domain of human 491 coronavirus spike",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Xia",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Yan",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "S"
                    ],
                    "last": "Agrawal",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Algaissi",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "K"
                    ],
                    "last": "Tseng",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Sci Adv",
            "volume": "5",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF58": {
            "ref_id": "b58",
            "title": "Emerging prophylaxis strategies against 493 COVID-19",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Agrawal",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "D"
                    ],
                    "last": "Goel",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Gupta",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Monaldi Arch Chest Dis",
            "volume": "90",
            "issn": "1",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF59": {
            "ref_id": "b59",
            "title": "Measures for diagnosing and treating 495 infections by a novel coronavirus responsible for a pneumonia outbreak 496 originating in Wuhan",
            "authors": [
                {
                    "first": "F",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Du",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "M"
                    ],
                    "last": "Ojcius",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Pan",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "China. Microbes Infect",
            "volume": "22",
            "issn": "",
            "pages": "74--83",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "29 pathogen was later identified as a novel coronavirus named as 2019 novel coronavirus 30 (2019-nCoV) by World Health Organization (WHO), or SARS-CoV-2 by the 31 Coronavirus Study Group (CSG) of the International Committee on Taxonomy of 32 Viruses (ICTV) on February 12, 2020, or human coronavirus 19 (hCoV-19) by a 33 group of virologists in China [2]. The WHO announced coronavirus disease 19 34 (COVID-19) as the official name of the disease. Respiratory droplet transmission is 35 the main route of transmission, and human-to-human transmission had been occurring 36 among close contacts since the middle of December 2019 [3]. WHO declared 37 COVID-19 as pandemic on March 11, 2020. As of April 22, 2020, a total of 2https://www.who.int/emergencies/diseases/novel-coronavirus-2019).40 Coronaviruses, which are enveloped non-segmented positive-sense RNA viruses, 41 belong to the family Coronaviridae. They are broadly distributed in humans and other 42 mammals [4]. Previously, six coronavirus species were known to cause human disease, 43 including HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV and 44 Middle East respiratory syndrome coronavirus (MERS-CoV) [5]. The first four 45 species caused only mild symptoms, but SARS-CoV and MERS-CoV have caused 46 4 more than 10 thousand cumulative infections in humans in the past two decades with 47 mortality rates of ~10% for SARS-CoV and ~34% for MERS-CoV, respectively [6-8]. 48 SARS-CoV-2 is the seventh number of the family of coronavirus that can infect 49 humans [9]",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "electron microscopy, cell culture, real-time reverse-transcription PCR (RT-PCR) and 81 next-generation sequencing [9]. Molecular tests for rapid detection of the causative 82 virus are urgently needed for early identification of infected patients; meanwhile, 83 RT-PCR, which combines the reverse transcription of RNA and amplification of 84 specific cDNA regions, remains the primary means of diagnosing SARS-CoV-2 [16]. 85 Normally, sputum, lower respiratory tract secretions, blood, urine or stool samples are 86 collected form suspected patients. Nasopharyngeal and oropharyngeal swabs are the 87 recommended upper respiratory tract specimen types for SARS-CoV-2 detection [17]. 88 The University of Hong Kong-Shenzhen Hospital enrolled a family of six patients 89 who travelled to Wuhan from Shenzhen between December 29, 2019 and January 4,",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": "Nasopharyngeal or throat swabs were collected. After RNA extraction, an 91 RT-PCR assay was performed to amplify the genes encoding the internal 92 RNA-dependent RNA polymerase (RdRp) and the surface spike (S) protein of 93 SARS-CoV-2. Phylogenetic analysis of the RT-PCR amplicons and two full genomes 94 by next-generation sequencing confirmed that the family was, indeed, infected by 95 SARS-CoV-2 [18]. Prof. Poon's group developed two 1-step quantitative RT-PCR 96 assays to detect the ORF1b and N genes of SARS-CoV-2. The assays were evaluated 97 using a panel of positive (RNA extracted from cells infected by SARS coronavirus) 98 and negative controls. The detection limits were found to be below 10 copies per 99 reaction, and samples from two SARS-CoV-2 infected patients were positive in the 100 tests [19]. Samples from all collections contained sputum, as well as nose and throat 101 swabs, with or without viral transport medium. RNA extraction and RT-PCR were 102 performed to amplify the RdRp, E and N genes of SARS-CoV-2. The assays were 103 highly sensitive and specific because they did not cross-react with other coronaviruses 104 [20]. 105 Collection of nasopharyngeal or oropharyngeal specimens may cause discomfort 106 and bleeding, especially in patients with thrombocytopenia [18]. This method also 107 requires close contact between healthcare workers and patients, which poses a risk of 108 transmission [17]. Consequently, neither nasopharyngeal nor oropharyngeal 109 specimens are ideal for serial monitoring of viral load. One study used saliva to screen 110 respiratory viruses among hospitalized patients without fever or respiratory symptoms 111 [21]. Prof. Yuen's group collected saliva from 12 Hong Kong patients with 112 7 laboratory-confirmed cases of coronavirus infection, and the novel coronavirus could 113 be detected in the saliva specimens of 11 patients (91.7%) by in-house one-step real 114 time RT-qPCR assay targeting the S gene [17], suggesting that saliva could be a 115 practical noninvasive specimen type. Several rapid diagnostic kits for SARS-CoV-2 116 detection are now commercially available. Among them, one is from the Beijing 117 Genome Institute (BGI). It can detect multiple pathogens using sequencing and 118 microarray technologies, and it has been approved for clinical use [16].",
            "latex": null,
            "type": "figure"
        },
        "FIGREF3": {
            "text": "Development of vaccines against COVID-19 infection120    Vaccine development is the most effective strategy to prevent and eliminate121 infectious disease. By learning from the vaccine development path of MERS and 122 SARS, several platforms, including DNA, mRNA, recombinant protein, and 123 adenoviral vector, are being investigated. Since S protein and its fragments, such as 124 S1, S2, RBD, and N protein, are prime targets for developing MERS and SARS 125 vaccines, it is expected that similar regions of SARS-CoV-2 could also be considered 126 as critical targets for COVID-19 vaccines [22, 23]. Since the genetic sequence of 127 SARS-CoV-2 has been released on 11 January 2020, more than 40 pharmaceutical 128 companies and academic institutions from many countries have engaged in actively 129 developing COVID-19 vaccines, and some candidates have entered efficacy 130 evaluation in animals and clinical trials.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF4": {
            "text": "Nucleic acid vaccines 132 Several major biotechnology companies have advanced nucleic acid platforms for Epidemic Preparedness Innovations (CEPI) to test the safety and 136 immunogenicity of a DNA vaccine named INO-4800 in Phase 1/2 clinical trial in 137 South Korea [24]. Both Moderna/NIH and CureVac are focusing on mRNA vaccine 138 development, and a safety clinical trial of Moderna's candidate vaccine mRNA-1273 139 with a sample size of 45 volunteers was performed in March 2020 [25].",
            "latex": null,
            "type": "figure"
        },
        "FIGREF5": {
            "text": "based on recombinant S or S1 protein of SARS-CoV and 142 MERS-CoV have been demonstrated to be efficacious in many studies [26-29]. 143 Clover Biopharmaceuticals is developing a vaccine consisting of a trimerized 144 SARS-CoV-2 S protein using their patented Trimer-Tag technology [30]. The 145 receptor-binding domain (RBD) in SARS-CoV-2 S protein was identified, and it was 146 further demonstrated that SARS-CoV-2 RBD exhibited significantly higher binding 147 affinity to ACE2 receptor compared to binding between SARS-CoV RBD and ACE2 148 [31], suggesting that the RBD-based SARS-CoV vaccines have the potential to be 149 developed for prevention of SARS-CoV-2 infections. RBD-based vaccines are now150",
            "latex": null,
            "type": "figure"
        },
        "FIGREF6": {
            "text": "Inactivated or live-attenuated virus vaccines 155 9 Whole inactivated or live-attenuated virus vaccines represent a traditional vaccine 156 strategy. Researchers at the University of Hong Kong have developed a live influenza 157 vaccine that expresses SARS-CoV-2 proteins [34]. Codagenix has developed a \"codon 158 deoptimization\" technology to attenuate viruses, and the company is exploring 159 COVID-19 vaccine strategies [35].",
            "latex": null,
            "type": "figure"
        },
        "FIGREF7": {
            "text": "Virus vector-based vaccines 161 Vaccines based on viral vectors offer a high level of protein expression and 162 long-term stability, and induce strong immune responses [36]. Johnson & Johnson is 163 developing an adenovirus-vectored vaccine using AdVac\u00ae / PER.C6\u00ae vaccine 164 platforms [37]. The first COVID-19 vaccine candidate based on adenovirus-vectored 165 vaccine developed by Chen Wei group entered human clinical testing (NCT04313127) 166 with unprecedented rapidity early on 16 March 2020. Another phase I safety trial of a 167 recombinant adenovirus vaccine candidate (Cansino Biologics Inc., Tianjin, China), 168 Ad5-nCoV, recruited 108 healthy adults in Wuhan, China in March 2020 [38]. Apart 169 from adenovirus vector-based vaccine, two lentivirus vector-based vaccine candidates, 170 COVID-19/aAPC and LV-SMENP-DC have been developed by Shenzhen 171 Geno-Immune Medical Institute. The COVID-19/aAPC vaccine was developed by 172 applying lentivirus modification including the SARS-CoV-2 minigenes and immune 173 modulatory genes, to the artificial antigen presenting cells (aAPCs). The Phase I 174 clinical trial consisting of 100 participants started on February 15, 2020 and the 175 estimated study completion date was December 31, 2024 (NCT04299724). The 176 LV-SMENP DC vaccine was developed by modifying DC with lentivirus vectors 177 10 expressing SARS-CoV-2 minigene SMENP and immune modulatory genes. The 178 Phase I clinical trial involving 100 patients was conducted on March 24, 2020 and the 179 estimated study completion date was also December 31, 2024 (NCT04276896) 180 (http://clinicaltrials.gov/). 181 As we all know that adjuvants play a critical role by enhancing immunogenicity of 182 the vaccine candidates and make dose viable in some vaccine platforms. So far, there 183 are at least 10 developers have engaged into developing adjuvanted COVID-19 184 vaccines. Vaccine developers Dynavax, Seqirus and GlaxoSmithKline have 185 committed to making some liscensed adjuvants including MF59, AS03 and CpG 1018 186 available for use [36]. 187 No matter which platform we take to develop the COVID-19 vaccines, researchers 188 need to carefully evaluate the effectiveness and safety of the candidate vaccine at each 189 step. In this situation, SARS-CoV-2 -specific animal models seems quite essential. 190 Until now, some different animal models are under developed, including hamsters, 191 ferrets, ACE2-transgenic mice and non-human primates [36].",
            "latex": null,
            "type": "figure"
        },
        "FIGREF8": {
            "text": "Therapeutic strategies to treat COVID-19 193 Specific drugs to treat the novel coronavirus will probably take several years to 194 develop and evaluate; however, a range of existing host-directed therapies are under 195 investigation. For example, clinical trials with protease inhibitors (clinical trials.gov: 196 NCT04276688, NCT04255017, and so on) and nucleotide analog remdesivir (clinical 197 trials.gov: NCT04280705, NCT04257656, NCT04252664, and so on) are ongoing in 198 China and the United States [39].",
            "latex": null,
            "type": "figure"
        },
        "FIGREF9": {
            "text": "ritonavir, two licensed HIV protease inhibitors, have been tested in 200 combination for efficacy in 99 COVID-19 patients in China, but the results suggested 201 no difference in the clinical outcome when compared with standard care [40]. Still, 202 one 54-year-old male, the third patient diagnosed with COVID-19 infection in Korea, 203 did show a significant decrease in viral load after lopinavir/ritonavir administration, 204and no virus titer was observed[41]. The preliminary results of a clinical trial on 205 favipiravir for the treatment of COVID-19 with a total of 80 patients showed that 206 favipiravir had more potent antiviral action than that of lopinavir/ritonavir[42].207 Future trials on patients with severe COVID-19 may help to confirm or exclude the 208 efficacy of lopinavir/ritonavir treatment. 209 Remdesivir, the antiviral agent, was designed for the Ebola virus infection, and it 210 was shown broad-spectrum antiviral activity against several RNA viruses [43]. 211 Remdesivir was shown to be highly effective in the control of SARS-CoV-2 infection 212 in vitro [44]. It was used to treat the first case of COVID-19 infection in the United 213 States, and the patient's clinical condition improved after only one day [45], 214 indicating the promise of Remdesivir, an anti-SARS-CoV-2 drug. Several clinical 215 trials are ongoing. 216 It has been demonstrated that SARS-CoV-2 uses the same cell entry receptor ACE2 217 as SARS-CoV [13]. The use of recombinant ACE2 (rACE2) to neutralize the virus 218 (clinical trials.gov: NCT04287686) is now under clinical investigation [39]. In vitro 219 studies have demonstrated that Vero cells pretreated with chloroquine are refractory to 220 SARS-CoV infection by interruption of the glycosylation process [46]. Chloroquine 221 12 has been demonstrated to be highly effective in the control of SARS-CoV-2 infection 222 in vitro [44]. Accordingly, chloroquine was first tested in clinical trial by Chinese 223 investigators on more than 100 patients with COVID-19, and it showed a reduction in 224 the duration of symptoms and exacerbation of pneumonia, along with radiological 225 improvement, leading to virus-negative seroconversion [47]. Hydroxychloroquine, a 226 less toxic derivative of chloroquine, was shown to be effective in inhibiting 227 SARS-CoV-2 infection in vitro [48]. However, no confirmed results from a 228 normalized clinical trial cliHydroxychloroquine, along with azithromycin, was tested 229 by French investigators on patients with COVID-19, and it showed that 100% patients 230 with COVID-19 treated with hydroxychloroquine in combination with azithromycin 231 exhibited virological cure on day 6 of the treatment. However, only 57.1% of patients 232 treated with hydroxychloroquine alone have exhibited virologocal cure [49]. However, 233 its use for treatment of COVID-19 outside of the hospital setting or a clinical trial was 234 against by the US FDA due to risk of heart rhythm problems 235 (https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hyd 236",
            "latex": null,
            "type": "figure"
        },
        "FIGREF10": {
            "text": "from the bronchoalveolar lavage fluid of a severe patient could be neutralized by sera241    from several other patients[51]. Another preliminary uncontrolled case involved 5 242 patients with severe COVID-19. After they were administered CP containing243 13 neutralizing antibodies (nAb), their clinical status improved [52]. One dose of 200 ml 244 of CP with the nAb titers above 1:640 was transfused to 10 patients with severe 245 COVID-19 as an addition to maximal supportive care and administration of antiviral 246 agents. The clinical symptoms were significantly improved within 3 days, and several 247 parameters were improved compared to pretransfusion, including decreased 248 C-reactive protein and increased lymphocyte counts [53]. Presently, 36 clinical trials 249 are ongoing worldwide (http://clinicaltrials.gov/).250 Previous research on MERS-CoV-and SARS-CoV-specific nAbs may provide 251 valuable guidelines for rapid design and development of SARS-CoV-2-specific nAbs. 252 Among the structural proteins of SARS-CoV-2, S fragments, such as S1-NTD, RBD 253 and S2, can be considered as targets for nAb development [12]. Polycloncal human 254 immunoglobulin G (IgG) derived from transgenic cows has been tested successfully 255 for MERS-CoV in animal models [54], and this strategy has been tested for safety in 256 clinical trials (clinical trials.gov: NCT02788188). Because of the high identity of the 257 RBD in SARS-CoV-2 and SARS-CoV, the cross-reactivity of SARS-CoV-specific 258 human monoclonal antibodies was tested on SARS-CoV-2, and it was found that only 259 CR3022 bound potently with SARS-CoV-2 [55], indicating that CR3022 might be a 260 potential therapeutic candidate for treatment of COVID-19 infections. Cocktails 261 consisting of antibodies specific for RBD and other regions in the S protein can be 262 considered to further improve the breadth and efficacy of nAbs against SARS-the HR2 domain of the spike proteins of SARS-CoV [56], MERS-CoV 267 [6] and SARS-CoV-2 [57, 58], have been shown to be effective against the fusion, 268 entry and replication of the corresponding coronavirus. A pan-corovirus fusion 269 inhibitor (EK1) were reported to be highly effective against divergent human 270 coronaviruses, including SARS-CoV, MERS-CoV, HCoV-OC43, HCoV-229E, 271 HCoV-NL-63, and SARS-CoV-2, as well as several bat SARS-related coronaviruses 272 (SARSr-CoVs) [58, 59]. A series of lipopeptides derived from EK1, which targeted 273 the HR1 domain, were highly potent in inhibiting entry and infection of divergent 274 human coronaviruses, including SARS-CoV-2. For example, the lipopeptide EK1C4 275 inhibited SARS-CoV-2 S protein-mediated membrane fusion with IC50 of 1.3 nM 276 [57]. Therefore, these peptides have great potential to be further developed as a 277 therapeutic or prophylactic for treatment or prevention of the current SARS-CoV-2 278 and MERS-CoV infection and future emerging and reemerging coronavirus 279 infections. 280 Researchers announced that darunavir, which is a second-generation HIV-1 281 protease inhibitor, inhibited SARS-CoV-2 infection in vitro and that the inhibition 282 efficiency was 280-fold over that of the untreated group [42]. Another trial 283 (NCT04304053) is looking at the efficacy of a durunavir/cobicistat plus choroquine 284 treatment [60]. Chinese herbal medicines, such as Radix Sophorae and Rhizoma 285 Polygoni Cuspidati, may contain agents against SARS-CoV-2 [42]. The combination 286 15 of traditional Chinese and Western medicine treatments is also promising. 287 Nonetheless, the efficacy and safety of all these potential candidates in the treatment 288 of COVID-19 need to be confirmed in further preclinical and clinical trials. However, 289 development of safe and effective COVID-19 therapeutics is often hampered by the 290 lack of valid COVID-19 animal models for evaluation their in vivo safety and efficacy",
            "latex": null,
            "type": "figure"
        },
        "FIGREF11": {
            "text": "virus infection among hospitalized adult patients with or without clinically 371 apparent respiratory infection: a prospective cohort study. Clin Microbiol Schematic diagram of SARS-CoV-2 structure and ACE2 receptor on the host cell surface",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "identity with SARS-CoV and MERS-CoV, respectively [11]. The genome of SARS-CoV-2 and other emerging pathogenic human coronaviruses encodes four and individuals showing signs of the disease. However, since SARS-CoV-2 is a newly discovered virus, the diagnostic toolkit is limited.",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "Here we reviewed recently published information about diagnostic approaches, as well as vaccine and treatment development, for SARS-CoV-2. Quickly identifying a person with SARS-CoV-2 infection is critical to control the continuing spread of the virus. The noninvasive specimen collection strategy has the advantage when collecting clinical specimens. It cannot be overstated that both vaccine development and investigation into potential drugs are subject to further studies to validate safety and efficacy, including, for example, immunization strategies, adjuvant selection, or establishment of animal models. International collaborations, or consortia, will promote COVID-19 and move vaccine development forward. Safety evaluation of candidate vaccines against SARS-CoV-2 is paramount, and this issue is related to the type of vaccines to be selected and immunogens to be designed. Potential therapeutics include lopinavir/ritonavir, remdesivir, chloroquine, hydroxychloroquine, CP and polyclonal/monoclonal antibodies. Again, however, clinical trials are needed for further confirmation of the efficacy and safety of these agents in treating COVID-19.The authors declare no conflicts of interest. Raj VS, Mou H, Smits SL, Dekkers DH, M\u00fcller MA, Dijkman R, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human online: http://www.who.int/emergencies/mers-cov/en/ Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382: 338 [10] Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis 2020; 26. [Epub ahead of print] [11] Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395: 565-74. [12] Jiang S, Hillyer C, Du L, Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol 2020. [Epub ahead of print] [13] Hoffmann M, Kleine-Weber H, Schroeder S, Kr\u00fcger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271-80. [14] Perlman S. Another decade, another coronavirus. N Engl J Med 2020; 382: 351 [15] Jiang S. Don't rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees. Nature 2020; 579: 321. [16] Pang J, Wang MX, Ang IYH, Tan SHX, Lewis RF, Chen JI, et al. Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): a systematic review. J Clin Med 2020; 9: 623. [17] To KK, Tsang OT, C. Chik-Yan Yip C, Chan KH, Wu TC, Chan JMC, et al. Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis 2020. [Epub ahead of print] 359 [18] Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020; 395: 363 [19] Chu DKW, Pan Y, Cheng SMS, Hui KPY, Krishnan P, Liu Y, et al. Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia. Clin Chem 2020; 66: 549-55. [20] Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro To KKW, Chan KH, Ho J, Pang PKP, Ho DTY, Chang ACH, et al. Respiratory",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}